[{"id":"b8f6cdd3-6953-45e6-a654-0d04207d6f01","acronym":"","url":"https://clinicaltrials.gov/study/NCT07481357","created_at":"2026-03-28T01:39:34.825Z","updated_at":"2026-03-28T01:39:34.825Z","phase":"Phase 1","brief_title":"A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT07481357","lead_sponsor":"Dong-A ST Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 02/01/2026","start_date":" 02/01/2026","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2026-03-18"},{"id":"6681fc89-1508-441a-b250-9c07d906a33e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07159672","created_at":"2025-09-13T08:45:49.996Z","updated_at":"2025-09-13T08:45:49.996Z","phase":"","brief_title":"Cohort Study on Nutritional, Metabolic, and Volumetric Assessment After Pancreaticoduodenectomy","source_id_and_acronym":"NCT07159672","lead_sponsor":"Marco Aurélio Ribeiro, PhD","biomarkers":" CXCL8 • IL4","pipe":"","alterations":" ","tags":["CXCL8 • IL4"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 07/01/2023","start_date":" 07/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2025-09-08"},{"id":"25644c79-5dff-4f90-909f-44d8053dcbb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT07148128","created_at":"2025-08-30T13:47:31.239Z","updated_at":"2025-08-30T13:47:31.239Z","phase":"Phase 1/2","brief_title":"Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.","source_id_and_acronym":"NCT07148128","lead_sponsor":"Auricula Biosciences Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/28/2025","start_date":" 07/28/2025","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-08-29"},{"id":"6a3b2e5b-0a7d-4873-a9a6-c4dee0b91e9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT07122466","created_at":"2025-08-16T14:02:18.822Z","updated_at":"2025-08-16T14:02:18.822Z","phase":"","brief_title":"Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy","source_id_and_acronym":"NCT07122466","lead_sponsor":"Northwell Health","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 10/17/2023","primary_completion_date":" 10/17/2023","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-08-14"},{"id":"b5fd76f4-90b4-4b35-893f-158f34042775","acronym":"MATTERS","url":"https://clinicaltrials.gov/study/NCT04467593","created_at":"2025-08-09T14:50:03.958Z","updated_at":"2025-08-09T14:50:03.958Z","phase":"","brief_title":"Safety Study of Whole Body Hyperthermia for Advanced Cancer","source_id_and_acronym":"NCT04467593 - MATTERS","lead_sponsor":"ElmediX","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 07/28/2021","start_date":" 07/28/2021","primary_txt":" Primary completion: 12/25/2024","primary_completion_date":" 12/25/2024","study_txt":" Completion: 12/25/2024","study_completion_date":" 12/25/2024","last_update_posted":"2025-08-05"},{"id":"70cc1b41-3bca-4660-a674-24287764e8ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT07094204","created_at":"2025-08-02T14:04:37.665Z","updated_at":"2025-08-02T14:04:37.665Z","phase":"Phase 1","brief_title":"A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors","source_id_and_acronym":"NCT07094204","lead_sponsor":"Astellas Pharma Inc","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 364","initiation":"Initiation: 07/31/2025","start_date":" 07/31/2025","primary_txt":" Primary completion: 11/30/2028","primary_completion_date":" 11/30/2028","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-07-30"},{"id":"955c5465-ea4e-4842-8504-e6f530022df5","acronym":"","url":"https://clinicaltrials.gov/study/NCT07043270","created_at":"2025-07-05T13:59:36.534Z","updated_at":"2025-07-05T13:59:36.534Z","phase":"Phase 2","brief_title":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","source_id_and_acronym":"NCT07043270","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2025-07-02"},{"id":"117ac5eb-6cd3-4e16-a1da-430f5c6a5c3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT07045571","created_at":"2025-07-05T14:02:04.651Z","updated_at":"2025-07-05T14:02:04.651Z","phase":"","brief_title":"MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer","source_id_and_acronym":"NCT07045571","lead_sponsor":"Yingbin Liu, MD, PhD, FACS","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 10/30/2022","start_date":" 10/30/2022","primary_txt":" Primary completion: 01/22/2026","primary_completion_date":" 01/22/2026","study_txt":" Completion: 07/22/2026","study_completion_date":" 07/22/2026","last_update_posted":"2025-07-01"},{"id":"0e00e05b-2578-4acd-967c-8c5eb860f4a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT07026916","created_at":"2025-06-21T13:17:33.061Z","updated_at":"2025-06-21T13:17:33.061Z","phase":"Phase 2","brief_title":"A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT07026916","lead_sponsor":"Genfleet Therapeutics (Shanghai) Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-06-18"},{"id":"b0c3d0f3-340f-42f7-821e-d51795e6563a","acronym":"","url":"https://clinicaltrials.gov/study/NCT07020221","created_at":"2025-06-14T13:52:20.544Z","updated_at":"2025-06-14T13:52:20.544Z","phase":"Phase 1/2","brief_title":"A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","source_id_and_acronym":"NCT07020221","lead_sponsor":"Verastem, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-06-13"},{"id":"b7d6e6ed-0f9e-4f9a-bf98-0d5c3c7402f8","acronym":"IPMN-GLP1RA","url":"https://clinicaltrials.gov/study/NCT07014709","created_at":"2025-06-14T13:55:08.029Z","updated_at":"2025-06-14T13:55:08.029Z","phase":"","brief_title":"Impact of GLP-1 Receptor Agonists on Patients With IPMN","source_id_and_acronym":"NCT07014709 - IPMN-GLP1RA","lead_sponsor":"Hôpital Fribourgeois","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/31/2025","start_date":" 05/31/2025","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2025-06-11"},{"id":"c6f24729-d5a7-4244-ad7f-a2cffb7113b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06917079","created_at":"2025-06-07T14:12:37.863Z","updated_at":"2025-06-07T14:12:37.863Z","phase":"Phase 1","brief_title":"BBO-11818 in Adult Subjects With KRAS Mutant Cancer","source_id_and_acronym":"NCT06917079","lead_sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 287","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2025-06-06"},{"id":"5561c46c-9fe6-437d-a39f-ed6b0feba556","acronym":"","url":"https://clinicaltrials.gov/study/NCT06998940","created_at":"2025-06-07T14:48:14.371Z","updated_at":"2025-06-07T14:48:14.371Z","phase":"Phase 3","brief_title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","source_id_and_acronym":"NCT06998940","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Vectibix (panitumumab) • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 01/06/2026","start_date":" 01/06/2026","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-05-31"},{"id":"38f6d35a-64a3-4650-878e-b5837dc695fe","acronym":"BLENTI","url":"https://clinicaltrials.gov/study/NCT06940778","created_at":"2025-09-07T01:21:55.747Z","updated_at":"2025-09-07T01:21:55.747Z","phase":"","brief_title":"LIQUID BIOPSY FOCUSING ON CIRCULATING TUMOR CELLS AND CIRCULATING TUMOR DNA AS PRECISION MEDICINE IN GASTROINTESTINAL TUMORS","source_id_and_acronym":"NCT06940778 - BLENTI","lead_sponsor":"Hospital do Coracao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 273","initiation":"Initiation: 01/10/2025","start_date":" 01/10/2025","primary_txt":" Primary completion: 06/10/2026","primary_completion_date":" 06/10/2026","study_txt":" Completion: 12/10/2026","study_completion_date":" 12/10/2026","last_update_posted":"2025-04-27"},{"id":"5e80e055-53fb-476a-823d-dd55cbbde48c","acronym":"CLARITI","url":"https://clinicaltrials.gov/study/NCT06947382","created_at":"2025-09-07T01:25:10.607Z","updated_at":"2025-09-07T01:25:10.607Z","phase":"","brief_title":"Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer","source_id_and_acronym":"NCT06947382 - CLARITI","lead_sponsor":"Immunovia, Inc.","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Completed","enrollment":" Enrollment 1066","initiation":"Initiation: 09/02/2024","start_date":" 09/02/2024","primary_txt":" Primary completion: 12/09/2024","primary_completion_date":" 12/09/2024","study_txt":" Completion: 01/06/2025","study_completion_date":" 01/06/2025","last_update_posted":"2025-04-27"},{"id":"9a5ed2f1-0ba5-4ea5-9318-4cb37ecaf26a","acronym":"VERIFI","url":"https://clinicaltrials.gov/study/NCT06947395","created_at":"2025-07-19T13:21:57.123Z","updated_at":"2025-07-19T13:21:57.123Z","phase":"","brief_title":"Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)","source_id_and_acronym":"NCT06947395 - VERIFI","lead_sponsor":"Immunovia, Inc.","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"],"overall_status":"Completed","enrollment":" Enrollment 386","initiation":"Initiation: 02/11/2025","start_date":" 02/11/2025","primary_txt":" Primary completion: 03/24/2025","primary_completion_date":" 03/24/2025","study_txt":" Completion: 04/07/2025","study_completion_date":" 04/07/2025","last_update_posted":"2025-04-27"},{"id":"f73e8116-9f3f-4e3c-8faf-7a232f425d23","acronym":"","url":"https://clinicaltrials.gov/study/NCT03861702","created_at":"2025-09-13T13:10:53.052Z","updated_at":"2025-09-13T13:10:53.052Z","phase":"Phase 2","brief_title":"Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:","source_id_and_acronym":"NCT03861702","lead_sponsor":"Nelson Yee","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 08/16/2023","primary_completion_date":" 08/16/2023","study_txt":" Completion: 09/27/2024","study_completion_date":" 09/27/2024","last_update_posted":"2025-04-18"},{"id":"9e8100a2-7197-4a5c-9158-5afa688f8f49","acronym":"PANSOTO","url":"https://clinicaltrials.gov/study/NCT06892054","created_at":"2025-09-07T02:06:33.580Z","updated_at":"2025-09-07T02:06:33.580Z","phase":"Phase 2","brief_title":"Sotorasib Combined with First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT06892054 - PANSOTO","lead_sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • irinotecan"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2025-03-24"},{"id":"381bf29b-94cb-4456-94ac-4f2cac19d9f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06852014","created_at":"2025-03-03T09:58:31.668Z","updated_at":"2025-03-03T09:58:31.668Z","phase":"","brief_title":"Effects of Peptamen 1.6 in Malnourished Patients (or At Risk) with Pancreatic Neoplasia Undergoing Cephalic Pancreaticoduodenectomy (CPD): a Mechanistic Study","source_id_and_acronym":"NCT06852014","lead_sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","biomarkers":" IL6 • TNFA","pipe":"","alterations":" ","tags":["IL6 • TNFA"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-28"},{"id":"8938bf1a-b3df-4fc1-a9f9-c9727dc17f53","acronym":"","url":"https://clinicaltrials.gov/study/NCT06843629","created_at":"2025-02-27T07:06:33.229Z","updated_at":"2025-02-27T07:06:33.229Z","phase":"","brief_title":"Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors","source_id_and_acronym":"NCT06843629","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-25"},{"id":"67ef8418-6d77-4d74-95d8-80f63ef20ed4","acronym":"SWOG S2001","url":"https://clinicaltrials.gov/study/NCT04548752","created_at":"2021-01-18T21:45:16.998Z","updated_at":"2025-02-25T12:27:43.236Z","phase":"Phase 2","brief_title":"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations","source_id_and_acronym":"NCT04548752 - SWOG S2001","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • cisplatin • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 02/22/2021","start_date":" 02/22/2021","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-24"},{"id":"2dee9945-f549-4f20-8162-2f885a4bbaeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05887492","created_at":"2023-06-02T14:06:23.752Z","updated_at":"2025-02-25T13:49:51.075Z","phase":"Phase 1/2","brief_title":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","source_id_and_acronym":"NCT05887492","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" STK11","pipe":" | ","alterations":" STK11 mutation","tags":["STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • TNG260"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 06/12/2023","start_date":" 06/12/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"3ed2719e-561e-41cf-943c-89926f1e9bc8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05306028","created_at":"2023-12-15T20:17:43.728Z","updated_at":"2025-02-25T13:40:56.951Z","phase":"Phase 2","brief_title":"Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)","source_id_and_acronym":"NCT05306028","lead_sponsor":"Fudan University","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"57288cee-f3b1-4cec-ae85-3fdf330023c7","acronym":"PBC039","url":"https://clinicaltrials.gov/study/NCT05396300","created_at":"2024-04-30T20:56:25.696Z","updated_at":"2025-02-25T13:41:03.634Z","phase":"Phase 1","brief_title":"A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05396300 - PBC039","lead_sponsor":"Weijia Fang, MD","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 positive","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • C-13-60"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/25/2022","start_date":" 05/25/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"}]